Department of Otorhinolaryngology-Head and Neck Surgery, Rush Sinus Program, Rush University Medical Center, Rush University Medical Center, Chicago, Illinois, U.S.A.
Laryngoscope. 2019 Dec;129(12):2675-2680. doi: 10.1002/lary.27886. Epub 2019 Feb 23.
Extranodal natural killer/T-cell lymphoma (ENKTL) is a highly aggressive tumor of the sinonasal tract associated with poor overall survival (OS). This study expands upon epidemiologic, prognostic, and treatment factors for OS and disease-specific survival (DSS), incorporating newly accessible chemotherapy data.
Retrospective population-based cohort study performed on cases of sinonasal ENKTL identified through the Surveillance, Epidemiology, and End Results database. Univariate Kaplan-Meier analysis and subsequent multivariate Cox-regression analysis were performed to evaluate prognostic and treatment variables for OS and DSS.
Four hundred and sixty cases of sinonasal ENKTL were identified. Five-year OS and DSS were 46% and 56%, respectively. On multivariate analysis, higher Ann Arbor stage was associated with worse OS (P < 0.001) and DSS (P < 0.001), whereas administration of radiotherapy was associated with improved OS (P < 0.001) and DSS (P = 0.001). Additionally, a higher age at diagnosis was associated with reduced OS (P = 0.024). Chemotherapy was associated with improved OS (P < .01) and DSS (P = .04) for Ann Arbor stage I disease. Surgery was not associated with improved survival.
This represents the first study to investigate the use of chemotherapy for the treatment of sinonasal ENKTL using population-based analysis. Radiation therapy and chemotherapy significantly improve survival in all Ann Arbor stage patients and early-stage patients, respectively. Early-stage disease is significantly associated with improved survival. With no established treatment regimen for sinonasal ENKTL, these findings suggest combination chemoradiation is an effective therapy for prolonged survival, especially in early stages of disease.
3 Laryngoscope, 129:2675-2680, 2019.
结外 NK/T 细胞淋巴瘤(ENKTL)是一种高度侵袭性的鼻窦肿瘤,与整体生存率(OS)较差相关。本研究扩展了 OS 和疾病特异性生存率(DSS)的流行病学、预后和治疗因素,纳入了新获得的化疗数据。
通过监测、流行病学和最终结果数据库对鼻窦 ENKTL 病例进行回顾性基于人群的队列研究。采用单变量 Kaplan-Meier 分析和随后的多变量 Cox 回归分析,评估 OS 和 DSS 的预后和治疗变量。
共确定了 460 例鼻窦 ENKTL 病例。5 年 OS 和 DSS 分别为 46%和 56%。多变量分析显示,较高的 Ann Arbor 分期与较差的 OS(P < 0.001)和 DSS(P < 0.001)相关,而放疗的应用与 OS(P < 0.001)和 DSS(P = 0.001)的改善相关。此外,诊断时年龄较高与 OS 降低相关(P = 0.024)。对于 Ann Arbor 分期 I 期疾病,化疗与 OS(P < 0.01)和 DSS(P = 0.04)的改善相关。手术与生存改善无关。
这是第一项使用基于人群的分析研究化疗治疗鼻窦 ENKTL 的研究。放疗和化疗均显著改善所有 Ann Arbor 分期患者和早期患者的生存率。早期疾病与生存率的提高显著相关。由于没有针对鼻窦 ENKTL 的既定治疗方案,这些发现表明联合放化疗是延长生存的有效治疗方法,尤其是在疾病的早期阶段。
3 Laryngoscope, 129:2675-2680, 2019.